ArticleAlimentary pharmacology & therapeutics2021

Letter: vedolizumab or a second anti-TNF-no difference in efficacy for primary biologic failures with IBD. Authors' reply.

Sara Rundquist et al.PubMed ↗Publisher ↗

No numbers read from the abstract.